Mississippi Boards Issue Joint Prohibition on Research-Grade Peptides
Three points warrant attention.
First, consent forms do not help. The boards state expressly that a provider cannot require or permit a patient to waive the provider’s duty of care, and that consent forms labeling a product “research-grade” do not reduce professional or legal liability. If a patient independently acquires and self-administers, the risk sits with the patient, but any professional involvement in recommending, supplying, prescribing, or administering is treated as the practice of medicine and is prohibited.
Second, the statement reaches sourcing and creates a reporting channel. Providers must purchase all prescription products, drugs, and ingredients from entities permitted by the Mississippi Board of Pharmacy, and unlicensed entities selling or shipping into Mississippi can be reported to that board. This is a meaningful expansion. It gives the boards a path to look upstream at suppliers, not just at licensees, and it puts out-of-state research chemical sellers shipping into Mississippi squarely in view.
Third, this is the second state board action of its kind in roughly three months. On May 26, 2026, the Alabama Board of Medical Examiners and Medical Licensure Commission issued an official notice using substantially the same framing, including the same position that “research-grade” consent forms are ineffective, and the same prohibition on routing these products through CRNPs, CNMs, or PAs. The Mississippi statement is broader in two respects: it is issued jointly with the nursing and pharmacy boards rather than by the medical board alone, and it adds the licensed-sourcing requirement.
What this means. Neither statement is a rule adopted through administrative rulemaking. Both are board policy statements. But board policy statements are the instrument through which licensure discipline gets imposed, so the practical exposure for licensees is immediate. The open question in both states is scope. Both notices use the phrase “non-FDA approved (research-grade),” which conflates two different things: true research chemical product sold under an RUO label, and preparations lawfully compounded by a 503A pharmacy or 503B outsourcing facility pursuant to a valid patient-specific prescription. Read narrowly, these notices target the former. Read literally, the “non-FDA approved” language could sweep in the latter. Providers, prescribers, and compounders operating in either state should not assume the narrow reading without counsel.
https://www.msbml.ms.gov/
